Penny Barnes



Phone: 902-473-2832
Mailing Address: 
Room 718 MacKenzie Building 5788 University Ave Halifax, NS B3H 1V8
Research Topics:
  • Clinical-pathologic correlation research in breast cancer
  • Quality assurance in immunohistochemistry
  • Cytopathology


Dr. Penny Barnes is a practicing Anatomical Pathologist at the QEII Health Sciences Centre in Halifax, NS with subspecialty interests in breast and cytopathology. She is co-chair of the Canadian Association of Pathologists (CAP-ACP) Annual Residents’ Review Course Committee, and a member of the Nova Scotia Breast Screening Program Advisory Council, the National Breast Cancer Pathology and Staging Multidisciplinary Expert Panel for the Canadian Partnership Against Cancer and the CAP-ACP National Standards Committee for High Complexity Testing.


  • MD: Memorial University of Newfoundland
  • Residency: Anatomical Pathology, Dalhousie University, Halifax, NS
  • Subspecialty Training: Breast Pathology, University of Nottingham, UK

Selected Publications

  • Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: What is the yield of routine reflex in situ hybridization testing? Gillian Charlotte Bethune, Alexandra Sophie Louise Pettit, Daniel Veldhuijzen van Zanten, Penelope Jane Barnes. Histopathology 2017; 70: 966-974.
  • Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro. Lynn N. Thomas, Emily R. Chedrawe, Penelope J. Barnes, Catherine K. L. Too. Breast Cancer Research and Treatment 2017; 164:27-40.
  • Invasive breast carcinomas with equivocal HER2 in situ hybridization test results: An ongoing challenge for pathologists and oncologists. Gillian C. Bethune, Daniel van Zanten, Tallal Younis, Penny J. Barnes. Canadian Journal of Pathology 2017; 9(4):30-40.
  • The impact of detection method and age on survival outcomes in triple-negative breast cancer: a population-based cohort analysis. Daniel Rayson, Jennifer L. Payne, James C.R. Michael, Kaitlyn M. Tsuruda, Mohamed Abdolell, Penny J. Barnes. Clinical Breast Cancer 2018; 18(5):955-960.
  • Isolated tumor cells in sentinel lymph nodes of primary invasive breast carcinoma: A cohort analysis M.A. Karkada, R. DeCoste, P.J. Barnes, D. Rayson and G. C. Bethune. Clinical Breast Cancer 2019; 19(4):286-91.
  • Fit-for-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines for Clinical Laboratories from the Canadian Association of Pathologists - Association Canadienne des Pathologistes (CAP-ACP). Carol C. Cheung, MD, PhD, JD, Penny Barnes, MD, Gilbert Bigras, MD, PhD, Jagdish Butany, MBBS, MS, Fiorella Calabrese, MD, Christian Couture, MD, PhD, Hala El-Zimaity, MD, PhD, Gabor Fischer, MD, PhD, Pierre O. Fiset, MD, PhD, John Garratt, RT, Laurette Geldenhuys, MBBCH, FFPATH, MMED, FIAC, MAEd, C. Blake Gilks, MD, Diana Ionescu, MD, Lisa Manning, BSc., Adnan Mansoor, MD, Robert Riddell, MD, Catherine Ross, MD, Sinchita Roy-Chowdhuri, MD PhD, Alan Spatz, MD, MSc, Paul E. Swanson, MD, Victor Tron, MD, Ming-Sound Tsao, MD, Hangjun Wang, MD, Zhaolin Xu, MD, and Emina E. Torlakovic, MD, PhD. Applied Immunohistochemistry and Molecular Morphology 2019; 27(10):699-714.
  • Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signaling, anti-apoptotic protein expression, and drug resistance in breast cancer cells. TM MacDonald, LN Thomas, E Daze, P Marignani, PJ Barnes, CKL Too. American Journal of Cancer Research 2019; 9(7):1484-1503.